ReviewCureus2026
Clinicopathologic Spectrum and Oxford MEST-C Scores in Adult IgA Nephropathy in Middle Eastern Cohorts: A PRISMA-Guided Literature Review With Crude Pooled Lesion Frequencies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, but Middle Eastern adults are under-represented in cohorts reporting Oxford MEST-C (mesangial, endocapillary, segmental, tubular atrophy/interstitial fibrosis, and crescent) lesions, limiting region-specific histologic risk profiling. We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review of observational adult (≥18 years) primary IgAN cohorts from Middle Eastern countries reporting Oxford MEST or MEST-C. MEDLINE (PubMed), Embase, and Scopus were searched from January 1, 2009, to November 24, 2025, with no language restrictions; citation searching (backward reference screening and forward citation tracking) was also performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale (NOS). For each MEST-C component, we calculated descriptive pooled proportions by summing numerators and denominators across cohorts with available extractable data; renal outcomes were synthesized narratively. Four retrospective cohorts (total n=528) from Iran, Turkey, and Saudi Arabia met eligibility criteria. Three cohorts contributed extractable lesion counts for M1, S1, and T1-2 (E1 data were available in two cohorts). Descriptive pooled frequencies were: mesangial hypercellularity (M1) 80.0%, endocapillary hypercellularity (E1) 35.7%, segmental glomerulosclerosis (S1) 58.5%, and tubulointerstitial scarring (T1-2) 56.4%. Crescent reporting was limited; where extractable, C≥1 was 28.9% in the Turkish cohort, and a sensitivity approximation incorporating a study reporting overall crescent frequency yielded ~27.6%. Where reported, T and crescent lesions were associated with worse renal outcomes. Formal heterogeneity testing and quantitative outcome meta-analysis were not performed due to a few clinically diverse cohorts. Risk of bias was low-to-moderate, mainly due to retrospective design, convenience sampling, and incomplete outcome reporting. Available Middle Eastern cohorts show frequent M1 and S1, with substantial T1-2 scarring and crescents in a sizeable minority of biopsied patients. These findings likely reflect advanced histologic injury at biopsy in tertiary-care cohorts and/or variation in case mix and biopsy/referral practices, underscoring the need for prospective regional registries with standardized pathology reporting and outcome definitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.